Intranasal Prime–Boost with Spike Vectors Generates Antibody and T-Cell Responses at the Site of SARS-CoV-2 Infection
There were significant differences in T-cell responses in spleens compared to lungs, and the intranasal boost was significantly superior to the intramuscular boost in generating sentinel immune effectors at the site of the virus encounter in the lungs. These data show that serious consideration should be given to intranasal boosting with anti-SARS-CoV-2 vaccines.
Authors
- Aleta Rios (ORCID: https://orcid.org/0000-0003-4735-5688)
- Jill Thompson (ORCID: https://orcid.org/0000-0001-5005-7257)
- David Masopust (ORCID: https://orcid.org/0000-0002-9440-3884)
- Richard G. Vile (ORCID: https://orcid.org/0000-0003-2192-9372)
- Michael A. Barry (ORCID: https://orcid.org/0000-0002-8568-5664)
- Haley Mudrick (ORCID: https://orcid.org/0000-0002-2716-5513)
- Jason M. Tonne
- Muriel Metko
- Rosa María Díaz
Institutions
- Mayo Clinic (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- University of Minnesota Medical Center (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Vaccines
- Published
- 2024-10-18
- DOI
- https://doi.org/10.3390/vaccines12101191
- Citations
- 4
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.96